As other gene editing programs fold or get sold, Arbor Biotechnologies has secured $73.9 million to advance its lead ...

The funds will facilitate the clinical progression of ABO-101, the company’s lead therapeutic candidate targeting PH1.

At a time when CRISPR companies have struggled, the Feng Zhang spinoff Arbor Biotechnologies gets a cash infusion to head to clinical trials.

Eric Green, the longtime director of the National Human Genome Research Institute, has abruptly left his role, according to ...

Create a stunning arched pergola that’s perfect for gardens, weddings, or selling for profit! 🏡✨ Whether you're adding charm to your outdoor space or looking for a high-demand woodworking project to ...

The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients ...

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investorsFinancing extends Arbor’s cash ...

“Arbor is developing a differentiated portfolio with first-in-class potential to deliver on the promise of CRISPR-based genetic medicines,” said Keith Crandell, co-founder and partner at ARCH ...

ARCH Venture Partners and TCGX led the financing ... curative genetic medicines for patients,” said Devyn Smith, CEO of Arbor Biotechnologies. “We are grateful for the support of this top ...

"Arbor is developing a differentiated portfolio with first-in-class potential to deliver on the promise of CRISPR-based genetic medicines,” said Keith Crandell, co-founder and partner at ARCH Venture ...